Is It Still Safe To Buy AstraZeneca plc?

In this strong market, should you still buy AstraZeneca plc (LON: AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m always searching for shares that can help ordinary investors like you make money from the stock market. However, many people are currently worried the market has been overheating. 

So right now I’m analysing some of the most popular companies in the FTSE 100, hoping to establish if they can continue to outperform in today’s uncertain economy. 

Today I’m looking at pharmaceutical giant AstraZeneca (LSE: AZN) (NYSE: AZN.US) to determine whether the shares are still safe to buy at 3,139p.

So, how’s business going?

AstraZeneca has fallen out of favour with the market during last year or so, as investors become more anxious about the company’s future. 

In particular, investors are worried about the company’s impending ‘patent cliff’, as AstraZeneca is going to lose the exclusive manufacturing rights to three of its key treatments during the next three years, which combined represent about 45% of the company’s sales.  

Thankfully, with so much of the company’s sales under threat, management has been quick to enact a turnaround plan. 

Indeed, as part of its plan to return to health, AstraZeneca has announced that it is going to cut nearly 10% of its workforce.  In addition, the company has been searching for strategic acquisitions, recently spending around $2 billion on three small biotech companies all with their own treatments in the latter stages of development.

Furthermore, AstraZeneca is hardly running low on ideas itself, with a strong pipeline of 84 new treatments, 13 of which are in the final stages of coming to market.

Expected growth

Unfortunately, while the company works hard to turn itself around, patent expirations and falling sales will continue dent earnings for the next few years. City forecasts currently predict earnings of $5.62 per share for this year (a fall of 12%) and $4.96 for 2014. 

Shareholder returns

AstraZeneca is well known for its strong dividend, and it appears this payout is not going to stop anytime soon. Indeed, the company’s dividend is covered around two-and-a-half times by earnings, giving the company plenty of room to maintain or even increase the payout. 

In addition, AstraZeneca’s dividend yield is currently 5.8% — larger than that of its peers in the pharmaceutical sector, which currently offer an average dividend yield of 4.6%. 


Even though AstraZeneca is one of the largest biotechnology companies in the world, due to concerns over its future, the firm trades at a discount to its rivals. 

AstraZeneca currently trades at a historic P/E of 11, while its peers trade at an average historic P/E of around 15. 

Foolish summary

Overall, AstraZeneca is going to have a rough time during the next few years, as the company loses exclusive manufacturing rights to some of its key products. 

That said, the company is working hard to cut costs and has a full pipeline of new treatments in development. So, all in all, I believe that AstraZeneca still looks safe to buy at 3,139p.

More FTSE opportunities

As well as AstraZeneca, I am also positive on the five FTSE shares highlighted within this exclusive wealth report.

Indeed, all five opportunities offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as “5 Shares You Can Retire On“!

Just click here for the report — it’s free.

In the meantime, please stay tuned for my next FTSE 100 verdict 

> Rupert does not own any share mentioned in this article.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Young Black woman looking concerned while in front of her laptop
Investing Articles

If I’d invested £10k in Greggs shares two years ago here’s what I’d have today

Harvey Jones wishes he'd bought Greggs shares two years ago and wonders whether the FTSE 250 stock still offers the…

Read more »

Young Caucasian woman with pink her studying from her laptop screen
Investing Articles

How I’d aim to turn an empty ISA into a £1m portfolio by targeting cheap shares

Harvey Jones is trawling the FTSE 100 for cheap shares to add to his Stocks and Shares ISA, in the…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

I’d start investing by buying shares with these 3 characteristics

Christopher Ruane explains how he would start investing if he was beginning from scratch, using a trio of key principles…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£3 a day now could earn me £5 a day of extra income in future. Here’s how.

By putting aside a few pounds each day, within 15 years our writer could be earning a fiver of extra…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

As the Raspberry Pi share price soars, is it set to be a great UK growth success?

What’s a super successful UK stock market IPO? It’s one we’ve just had, as the Raspberry Pi share price reaches…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

3 stocks that could create lasting passive income

When it comes to passive income, the most important thing is buying shares in companies that can keep performing well…

Read more »

Illustration of flames over a black background
Investing Articles

Just released: June’s higher-risk, high-reward stock recommendation [PREMIUM PICKS]

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility.

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Value Shares

Down 50%, this FTSE dividend stock looks like a steal to me

This FTSE stock’s been crushed if not quite left for dead. However, Edward Sheldon believes it's capable of a big…

Read more »